Cardiff Oncology (CRDF) Reports Q2 Loss, Lags Revenue Estimates

Cardiff Oncology shares have lost about 14.1% since the beginning of the year versus the S&P 500's gain of 8.6%. Cardiff Oncology (CRDF) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of$ 0.19. This compares to a loss of $0.26 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -10.53%. A quarter ago, it was expected that this molecular diagnostic company would post a loss of$ 0.19 ...